MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
16.49
-0.71 (-4.13%)
Dec 20, 2024, 4:00 PM EST - Market closed
MediWound Revenue
MediWound had revenue of $4.36M in the quarter ending September 30, 2024, a decrease of -8.81%. This brings the company's revenue in the last twelve months to $19.72M, down -21.01% year-over-year. In the year 2023, MediWound had annual revenue of $18.69M, down -29.48%.
Revenue (ttm)
$19.72M
Revenue Growth
-21.01%
P/S Ratio
8.00
Revenue / Employee
$197,200
Employees
100
Market Cap
177.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | 31.79M | 28.39M | 834.70% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organigram Holdings | 118.32M |
| Myomo | 25.24M |
| Stereotaxis | 25.14M |
| Fate Therapeutics | 13.45M |
| Molecular Partners AG | 7.11M |
| Orchestra BioMed Holdings | 2.65M |
| Quantum-Si incorporated | 2.27M |
MDWD News
- 25 days ago - MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 7 weeks ago - MediWound Is A Healthy Investment - Seeking Alpha
- 2 months ago - MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers - GlobeNewsWire
- 4 months ago - MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - GlobeNewsWire
- 4 months ago - MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 4 months ago - MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) - GlobeNewsWire